Will CAR-T get its first FDA approval for an autoimmune indication outside oncology, and when?

This is a company press release stating that the FDA cleared Cabaletta Bio's IND for a Phase 1/2 trial of CABA-201, a CD19 CAR-T therapy, in systemic sclerosis, an autoimmune disease. It bears on the prognosis because it documents FDA-authorized clinical development of CAR-T for a non-oncology autoimmune indication, a precursor step toward any future approval.

This is a company press release reporting positive clinical data and development updates for rese-cel, a CAR-T candidate being developed for autoimmune diseases including SLE, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris. It is relevant because it provides direct evidence on the progress of a non-oncology autoimmune CAR-T program that could contribute to the first FDA approval in this category.

This is a company press release stating that the FDA granted additional Fast Track designations for CABA-201 in dermatomyositis and systemic sclerosis, both autoimmune indications outside oncology. It is relevant because Fast Track status is a meaningful FDA regulatory signal that this CAR-T candidate is advancing toward potential autoimmune approval.

This is a company press release stating that the FDA granted Fast Track designation to KYV-101, a CAR-T therapy, for lupus nephritis and that a Phase 1 U.S. trial is active. It is relevant because it is direct evidence of FDA-recognized regulatory progress for a CAR-T autoimmune indication outside oncology, bearing on the likelihood and timing of first approval.

This is a company press release describing Kyverna's autoimmune CAR-T pipeline and regulatory timeline. It specifically states topline data are expected in 1H 2026 and a Biologics License Application filing is targeted for 2026, which is directly relevant to forecasting whether and when the first FDA autoimmune CAR-T approval outside oncology could occur.

This is a ClinicalTrials.gov study record for KYV-101, a CD19 CAR-T therapy. Because the forecasting question concerns first FDA approval of CAR-T for an autoimmune indication outside oncology, an interventional trial of an autoimmune CAR-T candidate is directly relevant evidence about development progress and timing.

This is Cabaletta Bio's pipeline page for CABA-201, a CD19 CAR-T therapy being developed for multiple autoimmune diseases including SLE, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris. It bears on the forecast because it is direct company evidence that an autoimmune CAR-T program exists and is advancing in clinical development, which informs the likelihood and timing of a first FDA autoimmune approval.

This is Kyverna Therapeutics' platform and pipeline page describing clinical trials and expanded access for CAR-T therapies in B-cell-driven autoimmune diseases such as stiff person syndrome, myasthenia gravis, multiple sclerosis, lupus nephritis, and systemic sclerosis. It is relevant because it shows an active developer pursuing autoimmune CAR-T indications that could plausibly lead to the first FDA approval in this category.

This is a ClinicalTrials.gov registration for a Phase 1/2 study of CAR-T therapy in systemic lupus erythematosus, an autoimmune disease outside oncology. It is directly relevant because it documents FDA-tracked clinical development of an autoimmune CAR-T candidate, which bears on the likelihood and timing of a first autoimmune approval.